Elevation in low density lipoprotein (LDL) cholesterol (LDL-C) is a causal risk factor for atherosclerotic established cardiovascular disease (ASCVD). Reduction of LDL-C with statins has been clearly demonstrated as a robust and cost-effective way of reducing the burden of ASCVD in individuals at risk. ASCVD is the leading cause of death and disability in Brazil and therefore prevention guidelines recommend LDL-C reduction with the aim of reducing disease burden in individuals at risk. Studies have shown a clear hiatus on awareness and treatment of cholesterol in Brazil. Thus, it became imperative to develop knowledge translation projects aiming at bridging the gap between science and clinical practice and ultimately leading to better outcomes. Cluster randomized clinical trials are the highest quality type of clinical research to test educational and active interventions aimed at changing behaviors or clinical practices. Therefore, this study is a pragmatic cluster randomized trial to assess the effect of a digitally enabled quality improvement intervention on LDL-C control in atherosclerotic established cardiovascular disease (ASCVD) patients.
Elevation in low density lipoprotein (LDL) cholesterol (LDL-C) is a causal risk factor for atherosclerotic established cardiovascular disease (ASCVD). Reduction of LDL-C with statins has been clearly demonstrated as a robust and cost-effective way of reducing the burden of ASCVD in individuals at risk. ASCVD is the leading cause of death and disability in Brazil and therefore prevention guidelines recommend LDL-C reduction with the aim of reducing disease burden in individuals at risk. Studies have shown a clear hiatus on awareness and treatment of cholesterol in Brazil. Thus, it became imperative to develop knowledge translation projects aiming at bridging the gap between science and clinical practice and ultimately leading to better outcomes. Cluster randomized clinical trials are the highest quality type of clinical research to test educational and active interventions aimed at changing behaviors or clinical practices.To our knowledge, data from this study will be crucial to leverage LDL-C treatment in Brazil, considering efforts to improve population health. The present study represents one of the first trials testing a quality improvement (QI) intervention targeted to LDL-C reduction in ASCVD patients conducted in a middle-income country. These results will address whether the proposed QI intervention is feasible and effective in these settings. Therefore, this study is a pragmatic cluster randomized trial to assess the effect of a digitally enabled QI intervention on LDL-C control in ASCVD patients. This study will have 2 phases. Phase 1 will be an observational phase prior to randomization of clusters with the objective to assess the baseline LDL-C levels achieved for target patients. Phase 2 will be an interventional phase, in which clusters will be randomized to the digitally enabled quality improvement intervention or usual care, with the objective to assess the effect of a digitally enabled QI intervention on control of LDL-C levels in ASCVD patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
1,465
Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including: * Knowledge of effective lipid lowering therapies * Clinical decision support * Audit and feedback on adherence to optimal clinical management * Audit and feedback on LDL-C control
Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.
Hospital da Bahia
Salvador, Estado de Bahia, Brazil
Hospital Santa Lúcia
Poços de Caldas, Minas Gerais, Brazil
Hospital e Maternidade Angelina Caron
Campina Grande do Sul, Paraná, Brazil
Hospital Regional Hans Dieter Schmidt
Joinville, Santa Catarina, Brazil
Centro de Pesquisa Clínica do Coração
Aracaju, Sergipe, Brazil
Hospital Universitário São Francisco de Assis
Bragança Paulista, São Paulo, Brazil
Instituto de Pesquisa Clínica de Campinas
Campinas, São Paulo, Brazil
Irmandade da Santa Casa de Misericórdia de Marilia
Marília, São Paulo, Brazil
Hospital Carlos Fernando Malzoni
Matão, São Paulo, Brazil
Hospital Universitário João de Barros Barreto
Belém, Brazil
...and 18 more locations
Phase 1: LDL-C levels
LDL-C levels measured at a single visit
Time frame: Baseline
Phase 2: LDL-C
LDL-C levels measured at the end of follow up of Phase 2
Time frame: 6 months
Phase 1: Prescribed lipid-lowering therapy
Percentage of patients on prescribed lipid-lowering therapy
Time frame: Baseline
Phase 1: Prescribed combination lipid-lowering therapy
Percentage of patients on prescribed combination lipid-lowering therapy
Time frame: Baseline
Phase 1: Prescribed intensive lipid-lowering therapy
Percentage of patients on prescribed intensive lipid-lowering therapy
Time frame: Baseline
Phase 1: Prescription of any statins
Percentage of prescription of any statins
Time frame: Baseline
Phase 1: Prescription of high intensity statins
Percentage of prescription of high intensity statins
Time frame: Baseline
Phase 1: Prescription of ezetimibe
Percentage of prescription of ezetimibe
Time frame: Baseline
Phase 1: Prescription of PCSK9 monoclonal antibody or siRNA PCSK9 inhibitors
Percentage of prescription of PCSK9 monoclonal antibody or siRNA PCSK9 inhibitors
Time frame: Baseline
Phase 1: LDL-C < 50 mg/dL
Percentage of patients with LDL-C \< 50 mg/dL
Time frame: Baseline
Phase 2: Prescribed lipid-lowering therapy
Percentage of patients on prescribed lipid-lowering therapy
Time frame: 6 months
Phase 2: Prescribed combination lipid-lowering therapy
Percentage of patients on prescribed combination lipid-lowering therapy
Time frame: 6 months
Phase 2: Prescribed intensive lipid-lowering therapy
Percentage of patients on prescribed intensive lipid-lowering therapy
Time frame: 6 months
Phase 2: Prescription of any statins
Percentage of prescription of any statins
Time frame: 6 months
Phase 2: Prescription of high intensity statins
Percentage of prescription of high intensity statins
Time frame: 6 months
Phase 2: Prescription of moderate intensity statins
Percentage of prescription of moderate intensity statins
Time frame: 6 months
Phase 2: Prescription of low intensity statins
Percentage of prescription of low intensity statins
Time frame: 6 months
Phase 2: Prescription of ezetimibe
Percentage of prescription of ezetimibe
Time frame: 6 months
Phase 2: Prescription of PCSK9 monoclonal antibody or siRNA PCSK9 inhibitors
Percentage of prescription of PCSK9 monoclonal antibody or siRNA PCSK9 inhibitors
Time frame: 6 months
Phase 2: LDL-C < 50 mg/dL
Percentage of patients with LDL-C \< 50 mg/dL
Time frame: 6 months
Phase 2: LDL-C relative change
Change in LDL-C relative to baseline
Time frame: 6 months
Phase 2: LDL-C reduction of ≥50%
Percentage of patients with LDL-C reduction of ≥50% relative to baseline
Time frame: 6 months
Phase 2: non-HDL-C relative change
Change in non-HDL-C relative to baseline
Time frame: 6 months
Phase 2: Barriers for drug prescription
Barriers for drug prescription at the system (cluster) and physician level
Time frame: 6 months
Phase 2: Adherence to prescribed lipid-lowering therapy
Patient´s adherence to prescribed lipid-lowering therapy
Time frame: 6 months
Phase 2: Barriers for drug adherence
Patient´s barriers for drug adherence
Time frame: 6 months
Phase 2: Intolerance to Statins
Percentage of patients with intolerance to Statins
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.